the benefits of glp 1 drugs beyond obesity GLP-1 agonists and changes in body mass and composition in adults with overweight or with or without type 2 diabetes mellitus: a systematic review and meta-analysis The Unstoppable Rise of GLP-1

GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial

[5] [6] The FLOW trial with semaglutide demonstrated significant reductions in kidney outcomes in patients with type 2 diabetes and chronic kidney disease

Impact of reducing obesity in PCOS: methods and treatment outcomes

Part of that reflects intensifying competition from Eli Lilly, which now commands 58% of total U.S

Lower doses are intended to give your body enough time to adjust and tolerate side effects

This makes it particularly effective for individuals with type 2 diabetes who may also need help managing blood sugar levels while losing weight